The YTH Domain-containing Protein Family: Emerging Players in Immunomodulation and Tumour Immunotherapy Targets

Overview

Journal Clin Transl Med

Publisher Wiley

Specialty General Medicine

Date 2024 Aug 13

PMID 39135292

Authors

Fenghe Li

Chong Zeng

Jie Liu

Lei Wang

Xiaorui Yuan

Li Yuan

Xiaomeng Xia

Wei Huang

Affiliations

Soon will be listed here.

Abstract

Background: The modification of N6-methyladenosine (m6A) plays a pivotal role in tumor by altering both innate and adaptive immune systems through various pathways, including the regulation of messenger RNA. The YTH domain protein family, acting as "readers" of m6A modifications, affects RNA splicing, stability, and immunogenicity, thereby playing essential roles in immune regulation and antitumor immunity. Despite their significance, the impact of the YTH domain protein family on tumor initiation and progression, as well as their involvement in tumor immune regulation and therapy, remains underexplored and lacks comprehensive review.

Conclusion: This review introduces the molecular characteristics of the YTH domain protein family and their physiological and pathological roles in biological behavior, emphasizing their mechanisms in regulating immune responses and antitumor immunity. Additionally, the review discusses the roles of the YTH domain protein family in immune-related diseases and tumor resistance, highlighting that abnormal expression or dysfunction of YTH proteins is closely linked to tumor resistance.

Key Points: This review provides an in-depth understanding of the YTH domain protein family in immune regulation and antitumor immunity, suggesting new strategies and directions for immunotherapy of related diseases. These insights not only deepen our comprehension of m6A modifications and YTH protein functions but also pave the way for future research and clinical applications.

Citing Articles

Emerging roles of N-methyladenosine in arsenic-induced toxicity.

Li R, Wu C, Zhao Y, Jiang S, Huang J, Huo X Heliyon. 2024; 10(22):e40473.

PMID: 39641074 PMC: 11617730. DOI: 10.1016/j.heliyon.2024.e40473.

The YTH domain-containing protein family: Emerging players in immunomodulation and tumour immunotherapy targets.

Li F, Zeng C, Liu J, Wang L, Yuan X, Yuan L Clin Transl Med. 2024; 14(8):e1784.

PMID: 39135292 PMC: 11319238. DOI: 10.1002/ctm2.1784.

References

Li R, Zhao H, Huang X, Zhang J, Bai R, Zhuang L . Super-enhancer RNA mA promotes local chromatin accessibility and oncogene transcription in pancreatic ductal adenocarcinoma. Nat Genet. 2023; 55(12):2224-2234. DOI: 10.1038/s41588-023-01568-8. View

Wang Z, Shang J, Qiu Y, Cheng H, Tao M, Xie E . Suppression of the METTL3-mA-integrin β1 axis by extracellular acidification impairs T cell infiltration and antitumor activity. Cell Rep. 2024; 43(2):113796. DOI: 10.1016/j.celrep.2024.113796. View

Luo Q, Fu B, Zhang L, Guo Y, Huang Z, Li J . Decreased Peripheral Blood Correlates with Markers of Autoimmune Response in Systemic Lupus Erythematosus. Dis Markers. 2020; 2020:8193895. PMC: 7334764. DOI: 10.1155/2020/8193895. View

He P, He C . m A RNA methylation: from mechanisms to therapeutic potential. EMBO J. 2021; 40(3):e105977. PMC: 7849164. DOI: 10.15252/embj.2020105977. View

Yu J, Chai P, Xie M, Ge S, Ruan J, Fan X . Histone lactylation drives oncogenesis by facilitating mA reader protein YTHDF2 expression in ocular melanoma. Genome Biol. 2021; 22(1):85. PMC: 7962360. DOI: 10.1186/s13059-021-02308-z. View

Zhao C, Xu G, Zhang X, Ye Y, Cai W, Shao Q . RNA mA modification orchestrates the rhythm of immune cell development from hematopoietic stem cells to T and B cells. Front Immunol. 2022; 13:839291. PMC: 9354743. DOI: 10.3389/fimmu.2022.839291. View

Xu C, Liu K, Ahmed H, Loppnau P, Schapira M, Min J . Structural Basis for the Discriminative Recognition of N6-Methyladenosine RNA by the Human YT521-B Homology Domain Family of Proteins. J Biol Chem. 2015; 290(41):24902-13. PMC: 4598999. DOI: 10.1074/jbc.M115.680389. View

Tanabe A, Tanikawa K, Tsunetomi M, Takai K, Ikeda H, Konno J . RNA helicase YTHDC2 promotes cancer metastasis via the enhancement of the efficiency by which HIF-1α mRNA is translated. Cancer Lett. 2016; 376(1):34-42. DOI: 10.1016/j.canlet.2016.02.022. View

Wang C, Gong J, Zhao Z, Zhu Q, Shu B, Hu J . mA demethylation of FOSL1 mRNA protects hepatoma cells against necrosis under glucose deprivation. Cell Death Differ. 2024; 31(8):1029-1043. PMC: 11303728. DOI: 10.1038/s41418-024-01308-3. View

10.

Kariko K, Buckstein M, Ni H, Weissman D . Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005; 23(2):165-75. DOI: 10.1016/j.immuni.2005.06.008. View

11.

Li Y, Jin H, Li Q, Shi L, Mao Y, Zhao L . The role of RNA methylation in tumor immunity and its potential in immunotherapy. Mol Cancer. 2024; 23(1):130. PMC: 11188252. DOI: 10.1186/s12943-024-02041-8. View

12.

Cai J, Chen Z, Zhang Y, Wang J, Zhang Z, Wu J . CircRHBDD1 augments metabolic rewiring and restricts immunotherapy efficacy via mA modification in hepatocellular carcinoma. Mol Ther Oncolytics. 2022; 24:755-771. PMC: 8908059. DOI: 10.1016/j.omto.2022.02.021. View

13.

Wen J, Xue L, Wei Y, Liang J, Jia W, Yong T . YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD-L1/VEGFA Axis. Adv Sci (Weinh). 2024; 11(13):e2307242. PMC: 10987122. DOI: 10.1002/advs.202307242. View

14.

Hao W, Dian M, Zhou Y, Zhong Q, Pang W, Li Z . Autophagy induction promoted by mA reader YTHDF3 through translation upregulation of FOXO3 mRNA. Nat Commun. 2022; 13(1):5845. PMC: 9532426. DOI: 10.1038/s41467-022-32963-0. View

15.

Sugiokto F, Saiada F, Zhang K, Li R . SUMOylation of the m6A reader YTHDF2 by PIAS1 promotes viral RNA decay to restrict EBV replication. mBio. 2024; 15(2):e0316823. PMC: 10865817. DOI: 10.1128/mbio.03168-23. View

16.

Dong L, Chen C, Zhang Y, Guo P, Wang Z, Li J . The loss of RNA N-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8 T cell dysfunction and tumor growth. Cancer Cell. 2021; 39(7):945-957.e10. DOI: 10.1016/j.ccell.2021.04.016. View

17.

Imai Y, Matsuo N, Ogawa S, Tohyama M, Takagi T . Cloning of a gene, YT521, for a novel RNA splicing-related protein induced by hypoxia/reoxygenation. Brain Res Mol Brain Res. 1998; 53(1-2):33-40. DOI: 10.1016/s0169-328x(97)00262-3. View

18.

Zhang X, Su T, Wu Y, Cai Y, Wang L, Liang C . N6-Methyladenosine Reader YTHDF1 Promotes Stemness and Therapeutic Resistance in Hepatocellular Carcinoma by Enhancing NOTCH1 Expression. Cancer Res. 2024; 84(6):827-840. DOI: 10.1158/0008-5472.CAN-23-1916. View

19.

Zhang C, Huang S, Zhuang H, Ruan S, Zhou Z, Huang K . YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation. Oncogene. 2020; 39(23):4507-4518. DOI: 10.1038/s41388-020-1303-7. View

20.

Fan Z, Ye M, Liu D, Zhou W, Zeng T, He S . Lactate drives the ESM1-SCD1 axis to inhibit the antitumor CD8 T-cell response by activating the Wnt/β-catenin pathway in ovarian cancer cells and inducing cisplatin resistance. Int Immunopharmacol. 2024; 137:112461. DOI: 10.1016/j.intimp.2024.112461. View